Cite
HARVARD Citation
Pernas, S. et al. (2018). Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet oncology. 19 (6), pp. 812-824. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Pernas, S. et al. (2018). Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet oncology. 19 (6), pp. 812-824. [Online].